Who
John Patrick Shannon Jr.
Director and Officer
Company insider
Files Form 4 as: Director and Officer, Xeris Biopharma Holdings; Officer, Xeris Pharmaceuticals; Chief Commercial Officer, Durata Therapeutics.
In numbers
- Trades disclosed
- 89
- Buys
- 8
- Sells
- 2
- Bought
- $527K
- Sold
- $526K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 24 Jul 2012
- Last trade
- 1 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Aug 2026filed 21 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $296K36,645 at $8.08 | filing |
| 1 Aug 2026filed 21 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $296K36,645 at $8.08 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $869K118,134 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $822K111,621 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $815K110,750 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $869K118,134 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $822K111,621 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $815K110,750 at $7.36 | filing |
| 30 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —478,436 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —639,639 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —639,639 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —478,436 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $176K24,907 at $7.08 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $100K64,265 at $1.55 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $39K25,136 at $1.55 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,265 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,136 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,900 at $0.00 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $11K2,900 at $3.94 | filing |
| 5 Jan 2026filed 6 Jan 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,265 at $0.00 | filing |
News
Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)XERS · themarketsdaily.com · 19 Oct 2026Comparing Corcept Therapeutics (NASDAQ:CORT) & Xeris Biopharma (NASDAQ:XERS)XERS · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name John Patrick Shannon Jr.; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.